Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230Phase 2Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jan 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in glioblastoma (GBM), sponsored by UT Health San Antonio. Started Jan 2022; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04559230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559230.